SGAM
FATE icon

Smith Group Asset Management’s Fate Therapeutics FATE Stock Holding History

Smith Group Asset Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-90
Closed -$5K – 308
2021
Q4 		$5K Hold
90
– – ﹤0.01% 342
2021
Q3 		$5K Hold
90
– – ﹤0.01% 347
2021
Q2 		$8K Hold
90
– – ﹤0.01% 311
2021
Q1 		$7K Sell
90
-2,490
-97% -$239K ﹤0.01% 291
2020
Q4 		$235K Hold
2,580
– – 0.01% 172
2020
Q3 		$103K Buy
+2,580
New +$90.1K 0.01% 196

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Smith Group Asset Management's FATE Position: Q1 2022 in Review

Smith Group Asset Management sold out of Fate Therapeutics (FATE) in Q1 2022, closing a stake of 90 shares — an estimated $5K sold.

Smith Group Asset Management first reported a position in FATE in Q3 2020 and held it in 6 quarters. The position peaked at $235K in Q4 2020. 250 funds tracked by Wall St. Rank hold FATE as of Q1 2022.

  • Smith Group Asset Management reported no remaining Fate Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Smith Group Asset Management sold 90 Fate Therapeutics shares in Q1 2022, an estimated $5K.
  • Smith Group Asset Management first reported a position in Fate Therapeutics in Q3 2020 and held it in 6 quarters.
  • Smith Group Asset Management's Fate Therapeutics position peaked at $235K in Q4 2020.
  • 250 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2022.

Based on Smith Group Asset Management's 13F filing for Q1 2022, filed 5 May 2022.